The role of interleukin-6 in monitoring severe case of coronavirus disease 2019
Tao Liu, Jieying Zhang, Yuhui Yang, Hong Ma, Zhenyu Li, Jiaoyue Zhang, Ji Cheng, Xiaoyun Zhang, Yanxia Zhao, Zihan Xia, Liling Zhang, Gang Wu, Jianhua Yi, Tao Liu, Jieying Zhang, Yuhui Yang, Hong Ma, Zhenyu Li, Jiaoyue Zhang, Ji Cheng, Xiaoyun Zhang, Yanxia Zhao, Zihan Xia, Liling Zhang, Gang Wu, Jianhua Yi
Abstract
Progression to severe disease is a difficult problem in treating coronavirus disease 2019 (COVID-19). The purpose of this study is to explore changes in markers of severe disease in COVID-19 patients. Sixty-nine severe COVID-19 patients were included. Patients with severe disease showed significant lymphocytopenia. Elevated level of lactate dehydrogenase (LDH), C-reactive protein (CRP), ferritin, and D-dimer was found in most severe cases. Baseline interleukin-6 (IL-6) was found to be associated with COVID-19 severity. Indeed, the significant increase of baseline IL-6 was positively correlated with the maximal body temperature during hospitalization and with the increased baseline of CRP, LDH, ferritin, and D-dimer. High baseline IL-6 was also associated with more progressed chest computed tomography (CT) findings. Significant decrease in IL-6 and improved CT assessment was found in patients during recovery, while IL-6 was further increased in exacerbated patients. Collectively, our results suggest that the dynamic change in IL-6 can be used as a marker for disease monitoring in patients with severe COVID-19.
Keywords: biomarker; coronavirus disease 2019; cytokine storm; disease monitoring; interleukin-6.
Conflict of interest statement
The authors declare that they have no conflict of interest.
© 2020 The Authors. Published under the terms of the CC BY 4.0 license.
Figures
References
- de Brito RC, Lucena‐Silva N, Torres LC, Luna CF, Correia JB, da Silva GA (2016) The balance between the serum levels of IL‐6 and IL‐10 cytokines discriminates mild and severe acute pneumonia. BMC Pulm Med 16: 170
- Channappanavar R, Perlman S (2017) Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol 39: 529–539
- Chen Y, Rubin P, Williams J, Hernady E, Smudzin T, Okunieff P (2001) Circulating IL‐6 as a predictor of radiation pneumonitis. Int J Radiat Oncol Biol Phys 49: 641–648
- Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, Alecock E, Lee J, Kremer J (2008) IL‐6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti‐tumour necrosis factor biologicals: results from a 24‐week multicentre randomised placebo‐controlled trial. Ann Rheum Dis 67: 1516–1523
- Guan W‐j, Ni Z‐y, Hu Y, Liang W‐h, Ou C‐q, He J‐x, Liu L, Shan H, Lei C‐l, Hui DS et al (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382: 1708–1720
- Gupta KK, Khan MA, Singh SK (2020) Constitutive inflammatory cytokine storm: a major threat to human health. J Interferon Cytokine Res 40: 19–23
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395: 497–506
- Liu J, Li S, Liu J, Liang B, Wang X, Wang H, Li W, Tong Q, Yi J, Zhao L et al (2020a) Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS‐CoV‐2 infected patients. EBioMedicine 55: 102763
- Liu Y, Sun W, Li J, Chen L, Wang Y, Zhang L, Yu L (2020b) Clinical features and progression of acute respiratory distress syndrome in coronavirus disease 2019. medRxiv 10.1101/2020.02.17.20024166 [PREPRINT]
- Luk HKH, Li X, Fung J, Lau SKP, Woo PCY (2019) Molecular epidemiology, evolution and phylogeny of SARS coronavirus. Infect Genet Evol 71: 21–30
- Magnan A, Mege JL, Escallier JC, Brisse J, Capo C, Reynaud M, Thomas P, Meric B, Garbe L, Badier M et al (1996) Balance between alveolar macrophage IL‐6 and TGF‐beta in lung‐transplant recipients. Marseille and Montreal Lung Transplantation Group. Am J Respir Crit Care Med 153: 1431–1436
- Maus U, Rosseau S, Knies U, Seeger W, Lohmeyer J (1998) Expression of pro‐inflammatory cytokines by flow‐sorted alveolar macrophages in severe pneumonia. Eur Respir J 11: 534–541
- Michot JM, Albiges L, Chaput N, Saada V, Pommeret F, Griscelli F, Balleyguier C, Besse B, Marabelle A, Netzer F et al (2020) Tocilizumab, an anti‐IL6 receptor antibody, to treat Covid‐19‐related respiratory failure: a case report. Ann Oncol 10.1016/j.annonc.2020.03.300
- Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, Sanvito F, Ponzoni M, Doglioni C, Cristofori P et al (2018) Monocyte‐derived IL‐1 and IL‐6 are differentially required for cytokine‐release syndrome and neurotoxicity due to CAR T cells. Nat Med 24: 739–748
- van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Fossa A, Simpson D, Capra M, Liu T, Hsieh RK et al (2014) Siltuximab for multicentric Castleman's disease: a randomised, double‐blind, placebo‐controlled trial. Lancet Oncol 15: 966–974
- Rose‐John S, Winthrop K, Calabrese L (2017) The role of IL‐6 in host defence against infections: immunobiology and clinical implications. Nat Rev Rheumatol 13: 399–409
- Saito LB, Diaz‐Satizabal L, Evseev D, Fleming‐Canepa X, Mao S, Webster RG, Magor KE (2018) IFN and cytokine responses in ducks to genetically similar H5N1 influenza A viruses of varying pathogenicity. J Gen Virol 99: 464–474
- Tanaka T, Narazaki M, Kishimoto T (2014) IL‐6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 6: a016295
- Wang WK, Chen SY, Liu IJ, Kao CL, Chen HL, Chiang BL, Wang JT, Sheng WH, Hsueh PR, Yang CF et al (2004) Temporal relationship of viral load, ribavirin, interleukin (IL)‐6, IL‐8, and clinical progression in patients with severe acute respiratory syndrome. Clin Infect Dis 39: 1071–1075
- Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y et al (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus‐infected pneumonia in Wuhan, China. JAMA 23: 1061–1069
- Wu Z, McGoogan JM (2020) Characteristics of and important lessons from the coronavirus disease 2019 (COVID‐19) outbreak in China: summary of a report of 72314 cases from the chinese center for disease control and prevention. JAMA 323: 1239–1242
- Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M et al (2020) Clinical course and outcomes of critically ill patients with SARS‐CoV‐2 pneumonia in Wuhan, China: a single‐centered, retrospective, observational study. Lancet Respir Med 8: 475–481
- Yiu HH, Graham AL, Stengel RF (2012) Dynamics of a cytokine storm. PLoS ONE 7: e45027
- Zhang X, Song K, Tong F, Fei M, Guo H, Lu Z, Wang J, Zheng C (2020) First case of COVID‐19 in a patient with multiple myeloma successfully treated with tocilizumab. Blood Adv 4: 1307–1310
- Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL et al (2020a) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579: 270–273
- Zhou Y, Fu B, Zheng X, Wang D, Zhao C, qi Y, Sun R, Tian Z, Xu X, Wei H (2020b) Aberrant pathogenic GM‐CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus. bioRxiv 10.1101/2020.02.12.945576 [PREPRINT]
Source: PubMed